title: Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.
abstract: Because of the necessary immunodepletion prior to cord blood transplantation as well as the immaturity of cord blood immune cells, recipients experience a high incidence of viral infection in addition to complications observed after hematopoietic stem cell transplantation, such as relapse and graft-versus-host disease. We describe current immunotherapeutic approaches to treating these complications, including the generation of antigen-specific T cells from cord blood, redirecting cord blood T cells using chimeric antigen receptors, and generating cord blood-derived natural killer cells and regulatory T cells.
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Hanley
authors.forename: Conrad Russell
authors.initials: CR
authors.lastname: Cruz
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
mesh_terms: D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects; D005312:Fetal Blood / Q000166:cytology; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007694:Killer Cells, Natural / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D019172:Transplantation Conditioning / Q000009:adverse effects; D014777:Virus Diseases / Q000209:etiology / Q000276:immunology / Q000628:therapy*
chemical_list: D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins
references.citation: J Immunother. 2010 Jan;33(1):96-105
references.pmid: 19952951
references.citation: Bone Marrow Transplant. 2009 Nov;44(10):621-6
references.pmid: 19802032
references.citation: Vaccine. 1998 Aug-Sep;16(14-15):1415-9
references.pmid: 9711781
references.citation: J Immunol. 2004 Jan 1;172(1):104-13
references.pmid: 14688315
references.citation: Hum Immunol. 1997 Aug-Sep;56(1-2):1-5
references.pmid: 9455488
references.citation: Nat Rev Cancer. 2003 Jan;3(1):35-45
references.pmid: 12509765
references.citation: Immunology. 1997 Mar;90(3):397-401
references.pmid: 9155647
references.citation: Pediatr Res. 2005 May;57(5 Pt 1):649-55
references.pmid: 15718362
references.citation: Semin Hematol. 2010 Jan;47(1):22-36
references.pmid: 20109609
references.citation: Clin Immunol. 2008 Jun;127(3):286-97
references.pmid: 18395491
references.citation: Cancer Res. 2006 Nov 15;66(22):10995-1004
references.pmid: 17108138
references.citation: Blood. 2010 Apr 1;115(13):2695-703
references.pmid: 20110422
references.citation: Nat Med. 2008 Nov;14(11):1264-70
references.pmid: 18978797
references.citation: Cell Immunol. 1999 Aug 1;195(2):81-8
references.pmid: 10448007
references.citation: Mol Ther. 2009 Aug;17(8):1453-64
references.pmid: 19384291
references.citation: Bone Marrow Transplant. 1991;7 Suppl 2:125
references.pmid: 1678975
references.citation: Blood. 1999 Nov 1;94(9):3101-7
references.pmid: 10556195
references.citation: Blood. 2005 Jan 15;105(2):750-8
references.pmid: 15374887
references.citation: Mol Ther. 2004 Jul;10(1):5-18
references.pmid: 15233937
references.citation: N Engl J Med. 1998 Nov 26;339(22):1565-77
references.pmid: 9828244
references.citation: Blood. 2007 Jul 1;110(1):433-40
references.pmid: 17371948
references.citation: Lancet. 1994 Oct 8;344(8928):983-5
references.pmid: 7934430
references.citation: Br J Haematol. 2009 Oct;147(2):200-6
references.pmid: 19796269
references.citation: Blood. 2008 Sep 1;112(5):2129-38
references.pmid: 18550852
references.citation: Nat Biotechnol. 2002 Jan;20(1):70-5
references.pmid: 11753365
references.citation: Cytotherapy. 2007;9(2):111-22
references.pmid: 17453963
references.citation: PLoS One. 2010 Feb 15;5(2):e9221
references.pmid: 20169160
references.citation: Exp Hematol. 2007 Sep;35(9):1388-97
references.pmid: 17656004
references.citation: N Engl J Med. 2004 Nov 25;351(22):2265-75
references.pmid: 15564543
references.citation: J Immunol. 2010 Jul 15;185(2):856-66
references.pmid: 20543110
references.citation: Br J Haematol. 2009 Oct;147(2):192-9
references.pmid: 19796268
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5
references.pmid: 19211796
references.citation: Bone Marrow Transplant. 2000 Dec;26(11):1251-4
references.pmid: 11149743
references.citation: Blood. 2009 Aug 27;114(9):1958-67
references.pmid: 19443656
references.citation: Science. 2002 Mar 15;295(5562):2097-100
references.pmid: 11896281
references.citation: Eur J Immunol. 1996 Nov;26(11):2666-70
references.pmid: 8921953
references.citation: Br J Haematol. 2009 Oct;147(2):185-91
references.pmid: 19796267
references.citation: J Exp Med. 1998 Aug 17;188(4):619-26
references.pmid: 9705944
references.citation: Nat Med. 2006 Oct;12(10):1160-6
references.pmid: 16998485
references.citation: Cytotherapy. 2004;6(1):15-22
references.pmid: 14985163
references.citation: J Immunother. 2010 Sep;33(7):684-96
references.pmid: 20664358
references.citation: Hum Immunol. 1997 Oct;57(2):69-79
references.pmid: 9438198
references.citation: Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):154-61
references.pmid: 19147098
references.citation: Curr Opin Oncol. 2010 Mar;22(2):122-9
references.pmid: 20180284
references.citation: Hum Gene Ther. 2007 Aug;18(8):712-25
references.pmid: 17685852
references.citation: Cell Mol Immunol. 2007 Oct;4(5):377-82
references.pmid: 17976318
references.citation: Blood. 2006 Apr 1;107(7):2643-52
references.pmid: 16352804
references.citation: Bone Marrow Transplant. 2004 Mar;33(6):605-11
references.pmid: 14743192
references.citation: Mol Ther. 2007 Oct;15(10):1744-50
references.pmid: 17637721
references.citation: Cytotherapy. 2010 Oct;12(6):743-9
references.pmid: 20429793
references.citation: Cytotherapy. 2003;5(6):479-84
references.pmid: 14660043
references.citation: Mol Ther. 2007 Apr;15(4):825-33
references.pmid: 17299405
references.citation: Blood. 2010 May 13;115(19):3861-8
references.pmid: 20215642
references.citation: Cell Immunol. 1997 Sep 15;180(2):132-42
references.pmid: 9341743
references.citation: Blood. 2005 Apr 15;105(8):3051-7
references.pmid: 15632206
references.citation: J Immunol. 1995 Aug 1;155(3):1151-64
references.pmid: 7636184
references.citation: Blood. 2006 Sep 1;108(5):1770-3
references.pmid: 16675712
references.citation: Blood. 2002 May 15;99(10):3493-9
references.pmid: 11986199
references.citation: Blood. 2004 Sep 1;104(5):1565-73
references.pmid: 15150080
references.citation: Br J Haematol. 2009 Oct;147(2):217-26
references.pmid: 19796271
references.citation: Transfus Apher Sci. 2010 Jun;42(3):257-63
references.pmid: 20395178
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
references.pmid: 17062687
references.citation: Br J Haematol. 2001 Jun;113(4):1060-71
references.pmid: 11442503
references.citation: Cancer Res. 2010 Jul 1;70(13):5249-58
references.pmid: 20530666
references.citation: Blood. 1998 Jul 1;92(1):11-8
references.pmid: 9639493
references.citation: Mol Ther. 2008 Mar;16(3):580-9
references.pmid: 18227839
references.citation: N Engl J Med. 2001 Jun 14;344(24):1815-22
references.pmid: 11407342
references.citation: N Engl J Med. 2004 Nov 25;351(22):2276-85
references.pmid: 15564544
references.citation: Blood. 1996 Aug 1;88(3):795-802
references.pmid: 8704232
references.citation: Immunol Invest. 2008;37(1):79-96
references.pmid: 18214801
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35
references.pmid: 17855649
references.citation: Cytotherapy. 2005;7(3):228-42
references.pmid: 16081349
references.citation: N Engl J Med. 1997 Aug 7;337(6):373-81
references.pmid: 9241126